Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Abingdon Health PLC ( (GB:ABDX) ) has shared an update.
Abingdon Health PLC announced the appointment of Tom Hayes as the new Chief Financial Officer, effective January 2025. With extensive experience in capital markets and AIM-listed companies, Tom’s appointment is seen as a strategic move to bolster Abingdon’s growth plans, especially as the company seeks to expand its operations into the USA. This change in leadership is expected to strengthen Abingdon Health’s financial and strategic capabilities, aligning with its ambitions to consolidate recent acquisitions and enhance its industry positioning.
More about Abingdon Health PLC
Abingdon Health PLC is a prominent med-tech contract service provider that offers an array of services to an international clientele. The company operates a CDMO division that specializes in lateral flow product development, regulatory assistance, technology transitions, and manufacturing services aimed at developing new assays or converting laboratory-based assays to lateral flow formats. Abingdon Health extends its expertise to sectors such as infectious diseases, clinical testing, animal health, and environmental testing. Additionally, the company provides regulatory services through Compliance Solutions and IVDeology to aid in the market introduction of medical devices across the USA, EU, and UK. Their Abingdon Simply Test range offers self-tests for consumer health management and is available through various channels.
YTD Price Performance: -29.55%
Average Trading Volume: 166,504
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £15.01M
For detailed information about ABDX stock, go to TipRanks’ Stock Analysis page.
